ROBERT F GAGEL to Antineoplastic Agents
This is a "connection" page, showing publications ROBERT F GAGEL has written about Antineoplastic Agents.
Connection Strength
0.719
-
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
Score: 0.157
-
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019 02 01; 26(2):241-250.
Score: 0.137
-
Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015; 204:227-49.
Score: 0.103
-
Cancer therapies and bone health. Curr Rheumatol Rep. 2010 Jun; 12(3):177-85.
Score: 0.075
-
Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm. Endocr Pract. 2009 Sep-Oct; 15(6):597-604.
Score: 0.071
-
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 11 01; 37(31):2916-2946.
Score: 0.036
-
The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998 Apr; 19(2):144-72.
Score: 0.032
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.020
-
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10; 28(5):767-72.
Score: 0.018
-
Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med. 2009 Jul; 266(1):99-113.
Score: 0.018
-
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6.
Score: 0.016
-
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8.
Score: 0.014
-
Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr; 19(5):651-8.
Score: 0.013
-
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
Score: 0.006
-
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun; 19(6):565-612.
Score: 0.004